Blue Owl discloses 8.46M Larimar Therapeutics (LRMR) shares in 13G/A

Rhea-AI Filing Summary

Blue Owl Capital Holdings LP filed an amended Schedule 13G reporting beneficial ownership of 8,464,663 Larimar Therapeutics common shares, representing 9.99 % of the class. This total includes 6,823,690 common shares and 1,640,973 shares issuable upon conversion of 250,000 Series A convertible preferred shares, which are subject to a 9.9% conversion blocker.

Blue Owl reports sole voting and dispositive power over all of these securities and states they were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Larimar Therapeutics.

Insights

Equity Ownership & Governance Analyst

Blue Owl reports a 9.99% passive stake in Larimar, including convertible preferred shares.

Blue Owl Capital Holdings LP discloses beneficial ownership of 8,464,663 Larimar common shares, or 9.99% of the class. The position combines 6,823,690 common shares with 1,640,973 common shares issuable from 250,000 shares of Series A convertible preferred stock.

The preferred stock is subject to a 9.9% conversion blocker, limiting how many common shares can be issued so that Blue Owl’s beneficial ownership does not exceed that threshold. Blue Owl has sole voting and dispositive power over the reported securities.

Blue Owl certifies the holdings are in the ordinary course of business and not for changing or influencing control of Larimar. Future ownership levels will depend on any conversions of the Series A preferred and subsequent share transactions disclosed in later beneficial ownership reports.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Larimar Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

517125100

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 517125100

1

Names of Reporting Persons

Blue Owl Capital Holdings LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,464,663.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,464,663.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,464,663.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reported securities represent (i) 6,823,690 shares of Common Stock and (ii) 1,640,973 shares of Common Stock issuable upon conversion of Series A Preferred Stock (as defined below). The percentage of class is calculated based upon 85,590,392 shares of Common Stock outstanding as of November 3, 2025, as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025, as decreased by (i) 2,500,000 shares of the Issuer's Common Stock exchanged for Series A Convertible Preferred Stock, and increased by (ii) 1,640,973 shares of Common Stock issuable upon conversion of Series A Preferred Stock.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Larimar Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: Three Bala Plaza East. Suite 506, Bala Cynwyd, PA, 19004
Item 2.
(a)	Name of person filing: This statement is filed by the Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."
(b)	Address or principal business office or, if none, residence: 399 Park Avenue New York, New York 10022
(c)	Citizenship: See response to Item 4 on the cover page.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 517125100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on the cover page. The reported securities include 6,823,690 shares of Common Stock and 1,640,973 shares of Common Stock issuable upon conversion of 250,000 shares of Series A convertible preferred stock (which would be convertible into 2,500,000 shares of Common Stock in the absence of a conversion blocker that limits the holder's benefit ownership to 9.9%). The filing of this statement shall not be construed as an admission that the Reporting Person is, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this statement.
(b)	Percent of class: See response to Item 11 on the cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on the cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on the cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on the cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on the cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Owl Capital Holdings LP

Signature:	/s/ Karen Hager
Name/Title:	Karen Hager / Chief Compliance Officer
Date:	02/12/2026

FAQ

What stake does Blue Owl Capital Holdings LP report in Larimar Therapeutics (LRMR)?

Blue Owl Capital Holdings LP reports beneficial ownership of 8,464,663 Larimar Therapeutics common shares, representing 9.99% of the outstanding class. This disclosure reflects Blue Owl’s position as of the reported date and includes both common and convertible preferred-linked shares.

How many Larimar Therapeutics common shares does Blue Owl directly hold?

Blue Owl holds 6,823,690 Larimar Therapeutics common shares. In addition, it reports beneficial ownership of extra shares issuable upon conversion of Series A convertible preferred stock, bringing its total reported beneficial stake to 8,464,663 common shares, or 9.99% of the class.

What role does the Series A convertible preferred stock play in Blue Owl’s LRMR ownership?

Blue Owl’s position includes 1,640,973 Larimar common shares issuable from 250,000 Series A convertible preferred shares. These preferred shares are convertible into common stock, but a blocker provision caps Blue Owl’s beneficial ownership at 9.9% of Larimar’s outstanding common shares.

What is the ownership percentage Blue Owl reports for Larimar Therapeutics common stock?

Blue Owl reports that its 8,464,663 beneficially owned Larimar common shares represent 9.99% of the outstanding class. This percentage is calculated using the company’s reported share count, adjusted for exchanged and convertible shares tied to the Series A preferred stock.

Does Blue Owl have voting and dispositive power over its Larimar Therapeutics shares?

Blue Owl reports sole voting and sole dispositive power over all 8,464,663 Larimar common shares it beneficially owns. It reports no shared voting or shared dispositive power, indicating one-party control over how these securities are voted and whether they are sold or transferred.

Is Blue Owl’s Larimar Therapeutics stake intended to influence control of the company?

Blue Owl certifies that its Larimar securities were acquired and are held in the ordinary course of business. It states they were not acquired and are not held to change or influence control of Larimar, but instead reflect a passive investment position under Schedule 13G.